"After receiving a green light from both U.S. and EU antitrust regulators, all regulatory closing conditions relating to the review of Novo Holdings A/S’s pending acquisition of Catalent Inc. have been fulfilled. The parties are now free to close the transaction, as well as Novo Nordisk’s subsequent acquisition of three Catalent manufacturing sites from Novo Holdings A/S.
The acquisition of Catalent is part of Novo Nordisk’s broader strategy to expand its manufacturing capabilities and secure supply chain resilience. By integrating Catalent’s extensive network of facilities and expertise, Novo Nordisk aims to enhance its ability to deliver innovative therapies to patients worldwide.
As previously announced, Novo Nordisk also plans to acquire three Catalent manufacturing sites from Novo Holdings A/S. This additional acquisition is expected to further strengthen Novo Nordisk’s manufacturing footprint and operational efficiency.
While the acquisition is expected to positively impact Novo Nordisk’s long-term growth, it will have a short-term impact on the company’s financial performance. The company anticipates a low single-digit negative impact on operating profit growth in 2024 and a mid single-digit negative impact in 2025. Additionally, the acquisition will increase the company’s debt levels and negatively impact net financial items.